Top Page
Helius Medical Technologies
(NASDAQ:HSDT)
Helius Medical Technologies (HSDT) vs. SPDR S&P 500 ETF (SPY)
Helius Medical Technologies Business Overview & Revenue Model
Helius Medical Technologies Earnings Call Summary
Helius Medical Technologies Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 941.00K | 520.00K | 644.00K | 787.00K | 522.00K | 661.00K |
| Gross Profit | 467.00K | -62.00K | 61.00K | 324.00K | 224.00K | -90.00K |
| EBITDA | -368.40M | -13.80M | -12.11M | -14.50M | -17.82M | -13.65M |
| Net Income | -370.37M | -11.74M | -8.85M | -14.07M | -18.13M | -14.13M |
Balance Sheet | ||||||
| Total Assets | 475.92M | 3.54M | 7.69M | 17.29M | 14.10M | 6.55M |
| Cash, Cash Equivalents and Short-Term Investments | 124.05M | 1.09M | 5.18M | 14.55M | 11.01M | 3.33M |
| Total Debt | 0.00 | 12.00K | 57.00K | 110.00K | 3.00K | 91.00K |
| Total Liabilities | 628.31M | 2.48M | 5.34M | 9.14M | 2.85M | 2.68M |
| Stockholders Equity | -152.39M | 1.06M | 2.35M | 8.15M | 11.26M | 3.87M |
Cash Flow | ||||||
| Free Cash Flow | -12.71M | -11.05M | -10.45M | -14.33M | -13.44M | -11.80M |
| Operating Cash Flow | -12.71M | -11.04M | -10.42M | -14.31M | -13.39M | -11.74M |
| Investing Cash Flow | -267.38M | -5.00K | -29.00K | -11.00K | -56.00K | -9.00K |
| Financing Cash Flow | 400.68M | 6.95M | 1.08M | 17.87M | 21.13M | 9.64M |
Helius Medical Technologies Technical Analysis
Helius Medical Technologies Risk Analysis
Helius Medical Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $282.09M | 22.44 | 10.53% | ― | 18.90% | 29.22% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
58 Neutral | $446.77M | -9.44 | -57.91% | ― | -4.39% | 11.70% | |
49 Neutral | $210.47M | -3.98 | -91.88% | ― | 18.44% | 25.42% | |
43 Neutral | $67.09M | -0.28 | -92.33% | ― | 4.65% | 68.71% | |
42 Neutral | $276.58M | -19.12 | ― | ― | 40.89% | -749.65% | |
39 Underperform | $123.08M | >-0.01 | ― | ― | 87.45% | 72.30% |
Helius Medical Technologies Corporate Events
On November 3, 2025, Solana Company, previously known as Helius Medical Technologies, shared a corporate presentation and a press release on their website. These documents, which are part of a Current Report, include forward-looking statements and are intended for informational purposes only, highlighting potential risks and uncertainties associated with the company’s future operations and financial projections.
On October 30, 2025, Solana Company held a special meeting where stockholders elected a new director and approved several proposals, including the issuance of shares related to strategic advisor warrants and cryptocurrency transactions. These decisions reflect the company’s strategic financial maneuvers to enhance its market position and operational capabilities, potentially impacting stakeholders by expanding its equity base and embracing cryptocurrency as part of its financial strategy.
On October 29, 2025, Solana Company announced an update on its SOL token holdings and staking performance, revealing an increase of 0.1 million SOL since October 6, 2025, bringing its total to over 2.3 million SOL. The company reported an average gross staking yield of 7.03% APY for October, outperforming the top 10 validators’ average by 36 basis points, highlighting its effective digital asset strategy and strong market positioning.
On October 20, 2025, Solana Company announced its decision to proceed with the scheduled registration for resale of shares purchased in a recent private placement, despite market volatility. This strategic move is intended to establish a foundation of committed long-term shareholders and position the company as a strong investment option for institutional investors. Solana Company aims to differentiate itself by actively accumulating Solana per share and leveraging capital markets to acquire additional Solana, with a focus on maximizing shareholder value and contributing to the growth of the Solana ecosystem.
On September 29, 2025, Helius Medical Technologies announced a corporate name change to Solana Company, reflecting its commitment to the Solana blockchain. The company has entered a non-binding letter of intent with the Solana Foundation, outlining collaboration terms and purchase options for SOL tokens. This move signifies HSDT’s dedication to becoming a key player in the blockchain industry, leveraging its digital asset treasury strategy to accumulate SOL and support Solana’s growth.
On September 24, 2025, Helius Medical Technologies announced side letter agreements granting one-time cash bonuses to its CEO and CFO, which will offset any future severance or bonuses. On September 25, 2025, the company filed a 510(k) submission with the FDA for the PoNS device label expansion, seeking approval for treating gait and balance deficits in chronic stroke patients. The submission, supported by data from their Stroke Registrational Program, highlights PoNS’ superior effectiveness in improving gait deficits, which could significantly impact stroke rehabilitation and patient care.
On September 22, 2025, Helius Medical Technologies announced its first acquisition of Solana (SOL) tokens as part of its digital asset treasury strategy, with over 760,190 SOL acquired at an average cost of $231. This move highlights Helius’s commitment to the Solana ecosystem and its strategy to maximize shareholder value by leveraging market conditions and retaining capital for future opportunities. The Solana blockchain, known for its rapid growth and high transaction volume, offers a ~7% native staking yield, making it a financially productive asset. Helius aims to support tokenized networks’ growth and security while continuing its neurotech and medical device operations.
On September 18, 2025, Helius Medical Technologies closed a private placement offering, raising over $500 million with the potential to reach $1.25 billion upon full exercise of issued warrants. The funds will be used to implement a digital asset treasury strategy focused on acquiring SOL, the native cryptocurrency of the Solana blockchain, to serve as the company’s primary treasury reserve asset. The offering was led by Pantera Capital and Summer Capital, with participation from various investors. Additionally, Joseph Chee was appointed as Executive Chairman, and the company plans to leverage Solana’s architecture for growth in decentralized finance and broader on-chain activities.
On September 15, 2025, Helius Medical Technologies, Inc. entered into a Sales Agreement with Clear Street LLC and Maxim Group LLC to offer and sell shares of its Class A common stock, with a potential aggregate sales price of up to $92.8 million. This agreement follows the termination of a previous sales agreement with Roth Capital Partners, LLC. The company has also agreed to pay commissions to the agents and cover certain legal expenses. Additionally, at a special meeting on May 23, 2025, stockholders approved an increase in the number of authorized shares of common stock to 800 million.
On September 15, 2025, Helius Medical Technologies announced the signing of securities purchase agreements with accredited investors, raising over $500 million in a private equity offering to implement a SOL treasury strategy. The company plans to use the proceeds to acquire SOL, the native cryptocurrency of the Solana blockchain, and establish its Solana treasury operations, aiming to leverage Solana’s architecture for yield-generating opportunities in decentralized finance and broader on-chain activity. This strategic move positions Helius to significantly enhance its presence in the crypto technology sector, with potential implications for increased institutional and retail access to the Solana ecosystem.